News Update
2022-03-16
NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that the one year distribution compliance period, under regulation S, for US investors who want to buy and trade NeoImmuneTech shares, has been lifted.
Dr Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech, Inc. said: “Today we celebrate the first anniversary our company started trading in Korea at the KOSDAQ stock exchange. We are proud of the progress we have made with the vast clinical development program of our lead asset NT-I7 (efineptakin alfa). With the lifting of the one year distribution compliance period, under regulation S, we are now pleased to welcome US investors who share our belief in our company’s potential and would be interested to become shareholders.”